January 9, 2023 Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia
December 7, 2022 Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
November 30, 2022 Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology
November 15, 2022 Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference
August 9, 2022 Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
